Mutation analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer cell lines: Implications for therapy

PLoS ONE

Volumn 2, Issue 12, 2007, Pages

  Estep, Anne L ^a   Palmer, Chana ^b   McCormick, Frank ^a,c   Rauen, Katherine A ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Canary Foundation   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; BRAF PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; PRIMER DNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; EXON; GENE DELETION; GENE FUNCTION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; HETEROZYGOSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; WESTERN BLOTTING; FEMALE; GENETICS; MUTATION; OVARY TUMOR; TUMOR CELL LINE;

BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MUTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; TRANSFECTION;

EID: 44249112553     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001279     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins, S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
3. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95: 484-486.
4. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, et al. (2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202: 336-340.
5. Ikediobi ON, Davies H, Bignell C, Edkins S, Stevens C, et al. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5: 2606-2612.
6. Campbell IG, Russell SE, Phillips WA (2005) PIK3CA mutations in ovarian cancer. Clin Cancer Res 11: 7042; author reply 7042-7043.
7. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, et al. (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11: 2875-2878.
8. Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL (2005) PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 25: 322.
9. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, et al. (2006) Sequence mutations and implification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5: 779-785.
10. Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, et al. (2000) Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 85: 160-165.
11. Schondorf T, Dostal A, Grabmann J, Gohring UJ (2000) Single mutations of the PTEN gene in recurrent ovarian carcinomas. J Soc Gynecol Investig 7: 313-316.
12. Tworek H, Peng R, Fetzer S, Werness BA, Piver MS, et al. (1999) Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors. Cancer Genet Cytogenet 112: 105-118.
13. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29: 218-224.
14. Yoon S, Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24: 21-44.
15. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, et al. (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822.
16. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947.
17. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih le M (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64: 6915-6918.
18. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, et al. (2006) Germline mutations in genes within the MAPK pathway cause cardiofacio-cutaneous syndrome. Science 311: 1287-1290.
19. Russell SE, McCluggage WG (2004) A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 203: 617-619.
20. Morita K, Ono Y, Fukui H, Tomita S, Ueda Y, et al. (2000) Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors. Pathol Int 50: 219-223.
21. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, et al. (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90: 378-381.
22. Chenevix-Trench G, Kerr J, Hurst T, Shih YC, Purdie D, et al. (1997) Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosomes Cancer 18: 75-83.
23. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351.
24. Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875-885.
25. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.
26. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, et al. (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38: 294-296.
27. Lau DH, Lewis AD, Ehsan MN, Sikic BI (1991) Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 51: 5181-5187.
28. Buick RN, Pullano R, Trent JM (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45: 3668-3676.
29. Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, et al. (2007) CFC and Noonan syndromes due to mutations in RAS/MAPK signaling pathway: genotype/phenotype relationships and overlap with Costello syndrome. J Med Genet ePub.
30. Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, et al. (2000) Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36: 357-361.
31. Cruz F 3rd, Rubin BP, Wilson D, Town A, Schroeder A, et al. (2003). Absence of PRAF and NRAS mutations in uveal melanoma. Cancer Res 63: 5761-5766.
32. Trovisco V, Soares P, Soares R, Magalhaes J, Sa-Couto P, et al. (2005) A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol 36: 694-697.
33. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812-3814.
34. Ng PC, Henikoff S (2006) Predicting the effects of amino Acid substitutions on protein function. Annu Rev Genomics Hum Genet 7: 61-80.
35. Bignell G, Smith R, Hunter C, Stephens P, Davies H, et al. (2006) Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 45: 42-46.
36. Davies H, Hunter C, Smith R, Stephens P, Greenman C, et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591-7595.
37. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, et al. (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66: 3987-3991.
38. Stephens P, Edkins S, Davies H, Greenman C, Cox C, et al. (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37: 590-592.
39. Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, et al. (2007) Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: Overlapping clinical manifestations with Costello syndrome. Am J Med Genet A 143: 799-807.
40. Delaney AM, Printen JA, Chen H, Fauman EB, Dudley DT (2002) Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol Cell Biol 22: 7593-7602.
41. Fukuda M, Gotoh I, Adachi M, Gotoh Y, Nishida E (1997) A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. Role of nuclear export signal of MAP kinase kinase. J Biol Chem 272: 32642-32648.
42. Mansour SJ, Resing KA, Candi JM, Hermann AS, Gloor JW, et al. (1994) Mitogen-activated protein (NUP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis. J Biochem. (Tokyo) 116: 304-314.
43. Bansal A, Ramirez RD, Minna JD (1997) Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines. Oncogene 14: 1231-1234.
44. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362.